Physician profile
Scott E Hirst
NPI 1194489294
$1,920.83
in general payments reported to CMS, 2019-2025
15 companies · $616 in 2025
The $616 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $470 · 2024: $569 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $958.48 | 2022-2025 | Rukobia, Apretude, Cabenuva |
| Abbvie INC. | $233.65 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.97 | 2022 | |
| Merck Sharp & Dohme LLC | $110.73 | 2022-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Janssen Biotech, INC. | $110.00 | 2022-2023 | Symtuza |
| Gilead Sciences, INC. | $106.33 | 2023-2025 | |
| Glaxosmithkline, LLC. | $75.87 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Theratechnologies INC. | $48.82 | 2023-2024 | Egrifta, Trogarzo |
| Novo Nordisk INC | $36.18 | 2023-2024 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $26.75 | 2022 | |
| Pfizer INC. | $25.53 | 2022-2023 | |
| Amgen INC. | $16.85 | 2024 | Repatha |
| Idorsia Pharmaceuticals US INC | $16.78 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.48 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $15.41 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hirst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.